Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-26-438199·Bain Capital Life Sciences Opportunities IV, L.P.
Schedule 13G ownership disclosure
ADC THERAPEUTICS SA
Common Shares, par value CHF 0.08 per share · CUSIP: H0036K147
Event date: 2026-10-22
- Filing-level shares
- 14,825,625
- Percent of class
- 9.99%
- Bain Capital Life Sciences Opportunities IV, L.P.
Shares: 14,825,625 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-438199
- Form type
- SCHEDULE 13G
- Filer
- Bain Capital Life Sciences Opportunities IV, L.P.
- CIK
- CIK 2015553
- Filed
- Oct 29, 2026
- Reporting period
- Oct 22, 2026
- Description
- Schedule 13G beneficial ownership